CONTACT US
Home > Inhibitors/Agonists> > Dalazatide
1081110-69-1-Dalazatide Dalazatide

Dalazatide

For research use only. Not for therapeutic Use.

  • CAT Number: I025520
  • CAS Number: 1081110-69-1
  • Molecular Formula: C184H296N57O55PS7
  • Molecular Weight: 4442.13
  • Purity: 98%
Inquiry Now
Related Small Molecules: IYPTNGYTR acetate     Suzetrigine     HCV-IN-29    

Dalazatide (Cat No.:I025520) is a synthetic peptide with immunomodulatory properties. It is derived from a toxin found in the venom of a sea anemone. Dalazatide selectively targets a specific potassium ion channel in immune cells, inhibiting their activation and reducing inflammation. This peptide has shown potential in the treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, by suppressing the immune response without causing widespread immunosuppression.


Catalog Number I025520
CAS Number 1081110-69-1
Synonyms

Dalazatide; SHK186; SHK 186; SHK-186

Molecular Formula C184H296N57O55PS7
Purity 98%
Target Potassium Channel
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name o-PHOSPHONO-L-Tyrosyl-2-(2-(2-aminoethoxy)ethoxy)acetyl(potassium channel toxin kappa-stichotoxin-shela stoichactis helianthus (caribbean sea anemone)) peptidamide
InChI InChI=1S/C184H296N57O55PS7/c1-14-94(5)139-172(283)223-124(79-138(254)255)162(273)238-144(100(11)249)176(287)236-140(95(6)15-2)178(289)240-68-33-46-135(240)171(282)217-112(41-24-28-61-187)152(263)224-125(82-242)163(274)212-116(45-32-66-204-182(197)198)153(264)229-134-91-304-303-89-132-168(279)214-114(43-30-64-202-180(193)194)148(259)210-113(42-25-29-62-188)156(267)237-143(99(10)248)175(286)232-130(147(258)206-81-137(253)234-141(97(8)246)174(285)227-129(145(192)256)86-299-301-90-133(169(280)235-139)231-166(277)128(85-245)233-179(290)184(58-34-67-205-183(199)200,295-71-70-294-69-63-189)241(101(12)250)177(288)109(190)74-104-49-53-108(54-50-104)296-297(291,292)293)87-300-302-88-131(228-154(265)117(55-56-136(191)252)215-158(269)120(75-102-35-18-16-19-36-102)218-146(257)96(7)208-173(284)142(98(9)247)239-170(134)281)167(278)213-111(40-23-27-60-186)150(261)222-123(78-106-80-201-92-207-106)161(272)226-126(83-243)164(275)216-118(57-72-298-13)155(266)209-110(39-22-26-59-185)149(260)220-122(77-105-47-51-107(251)52-48-105)159(270)211-115(44-31-65-203-181(195)196)151(262)219-119(73-93(3)4)157(268)225-127(84-244)165(276)221-121(160(271)230-132)76-103-37-20-17-21-38-103/h16-21,35-38,47-54,80,92-100,109-135,139-144,242-249,251H,14-15,22-34,39-46,55-79,81-91,185-190H2,1-13H3,(H2,191,252)(H2,192,256)(H,201,207)(H,206,258)(H,208,284)(H,209,266)(H,210,259)(H,211,270)(H,212,274)(H,213,278)(H,214,279)(H,215,269)(H,216,275)(H,217,282)(H,218,257)(H,219,262)(H,220,260)(H,221,276)(H,222,261)(H,223,283)(H,224,263)(H,225,268)(H,226,272)(H,227,285)(H,228,265)(H,229,264)(H,230,271)(H,231,277)(H,232,286)(H,233,290)(H,234,253)(H,235,280)(H,236,287)(H,237,267)(H,238,273)(H,239,281)(H,254,255)(H4,193,194,202)(H4,195,196,203)(H4,197,198,204)(H4,199,200,205)(H2,291,292,293)/t94-,95-,96-,97+,98+,99+,100+,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130?,131-,132-,133-,134-,135-,139-,140-,141-,142-,143-,144-,184+/m0/s1DownloadInChIKeyGORAHSAIYZMTHZ-LBFSFEBVSA-NSearch the web for this InChIKeySmilesCC[C@H](C)[C@@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)C2CSSC[C@@H]3NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc6ccc(O)cc6)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](Cc7c[nH]cn7)NC(=O)[C@H](CCCCN)NC3=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC1=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@@](CCCNC(=N)N)(OCCOCCN)N(C(=O)C)C(=O)[C@@H](N)Cc9ccc(OP(=O)(O)O)cc9DownloadData Source for o-PHOSPHONO-L-Tyrosyl-2-(2-(2-aminoethoxy)ethoxy)acetyl(potassium channel toxin kappa-stichotoxin-shela stoichactis helianthus (caribbean sea anemone)) peptidamideList AcronymsFDA SRS (FDA Substance Registration System)Click on 1081110-69-1's icon or row to pin it open.
InChIKey GORAHSAIYZMTHZ-LBFSFEBVSA-N
SMILES CC[C@@H]([C@@H]1NC([C@@H](NC([C@@H](NC([C@@](OCCOCCN)(N(C([C@H](Cc2ccc(OP(O)(O)=O)cc2)N)=O)C(C)=O)CCCNC(N)=N)=O)CO)=O)CSSC[C@@H](C(N)=O)NC([C@H]([C@H](O)C)NC(CNC(C3CSSC[C@@H]4NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H]5CCCN5C([C@H]([C@H](CC)C)NC([C@H]([C@H](O)C)NC([C@@H](NC1=O)CC(O)=O)=O)=O)=O)=O)CCCCN)=O)CO)=O)CCCNC(N)=N)=O)CSSC[C@@H](C(NC(C(NC(C(N[C@H](C(N3)=O)[C@H](O)C)=O)CCCCN)=O)CCCNC(N)=N)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC4=O)CCCCN)=O)Cc6nc[nH]c6)=O)CO)=O)CCSC)=O)CCCCN)=O)Cc7ccc(O)cc7)=O)CCCNC(N)=N)=O)CC(C)C)=O)CO)=O)Cc8ccccc8)=O)=O)=O)C)=O)Cc9ccccc9)=O)CCC(N)=O)=O)=O)=O)=O)=O)C
Reference

1: Tarcha EJ, Olsen CM, Probst P, Peckham D, Muñoz-Elías EJ, Kruger JG, Iadonato SP. Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial. PLoS One. 2017 Jul 19;12(7):e0180762. doi: 10.1371/journal.pone.0180762. PMID: 28723914; PMCID: PMC5516987.
2: Prentis PJ, Pavasovic A, Norton RS. Sea Anemones: Quiet Achievers in the Field of Peptide Toxins. Toxins (Basel). 2018 Jan 8;10(1):36. doi: 10.3390/toxins10010036. PMID: 29316700; PMCID: PMC5793123.
3: Tajti G, Wai DCC, Panyi G, Norton RS. The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides. Biochem Pharmacol. 2020 Nov;181:114146. doi: 10.1016/j.bcp.2020.114146. Epub 2020 Jul 10. PMID: 32653588.
4: Liao Q, Feng Y, Yang B, Lee SM. Cnidarian peptide neurotoxins: a new source of various ion channel modulators or blockers against central nervous systems disease. Drug Discov Today. 2019 Jan;24(1):189-197. doi: 10.1016/j.drudis.2018.08.011. Epub 2018 Aug 27. PMID: 30165198.
5: Tanner MR, Pennington MW, Chauhan SS, Laragione T, Gulko PS, Beeton C. KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis. Arthritis Res Ther. 2019 Jan 7;21(1):6. doi: 10.1186/s13075-018-1783-9. PMID: 30612588; PMCID: PMC6322314.

Request a Quote